Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: Is dose modification necessary in obese subjects?

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 666-673

  Hamilton, Rhonda ^a   Thai, Xia C ^b   Ameri, Darius ^a   Pai, Manjunath P ^c  

^a Winchester Hospital   (United States)

^b Cambridge Health Alliance ^*  (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Bariatric; Oxazolidinones; Pharmacodynamics; Pharmacokinetics; Surgery

Indexed keywords

LINEZOLID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; OBESITY; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; ROUX Y ANASTOMOSIS; SINGLE DRUG DOSE; STOMACH BYPASS; WEIGHT REDUCTION;

ACETAMIDES; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GASTRIC BYPASS; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; SERUM; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84873604113     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks431     Document Type: Article

References (28)

1. The NHS Information Centre, Lifestyle Statistics. Statistics on Obesity, Physical Activity and Diet: England, 2012. http://www.ic.nhs.uk/webfiles/publications/003_Health_Lifestyles/OPAD12/Statistics_on_Obesity_Physical_Activity_and_Diet_England_2012.pdf (31 August 2012, date last accessed).
2. Ogden CL, Carroll MD, Kit BK et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307: 483-90.
3. Lee SM, Pryor AD. Future directions in bariatric surgery. Surg Clin North Am 2011; 91: 1373-95.
4. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010; 11: 41-50.
5. Magee SR, Shih G, Hume A. Malabsorption of oral antibiotics in pregnancy after gastric bypass surgery. J Am Board Fam Med 2007; 20: 310-3.
6. Rogers CC, Alloway RR, Alexander JW et al. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant 2008; 22: 281-91.
7. Wills SM, Zekman R, Bestul D et al. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy 2010; 30: 86e-90e.
8. Park DM, Shah DD, Egorin MJ et al. Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. J Neurooncol 2009; 93: 279-83.
9. Rubio IG, Galrao AL, Santo MA et al. Levothyroxine absorption in morbidly obese patients before and after Roux-En-Y gastric bypass (RYGB) surgery. Obes Surg 2011; 22: 253-8.
10. Padwal RS, Gabr RQ, Sharma AM et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 2011; 34: 1295-300.
11. De Smet J, Colin P, De Paepe P et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother 2012; 67: 226-9.
12. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2012; 66 Suppl 4: iv7-15.
13. Stein GE, Schooley SL, Peloquin CA et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39: 427-32.
14. Mersfelder TL, Smith CL. Linezolid pharmacokinetics in an obese patient. Am J Health Syst Pharm 2005; 62: 464-7.
15. Tsuji Y, Hiraki Y, Matsumoto K et al. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand J Infect Dis 2012; 44: 626-9.
16. Meagher AK, Forrest A, Rayner CR et al. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003; 47: 548-53.
17. Abe S, Chiba K, Cirincione B et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol 2009; 49: 1071-8.
18. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles, CA: Biomedical Simulations Resource, 2009.
19. Akaike H. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 1979; 66: 237-42.
20. Ogden CL, Fryar CD, Carroll MD et al. Mean body weight, height, and body mass index, United States 1960-2002. Adv Data 2004; 347: 1-17.
21. Dehghanyar P, Burger C, Zeitlinger M et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 2005; 49: 2367-71.
22. Linezolid - EUCAST Rationale Document. Rationale for the EUCAST Clinical Breakpoints. 2005. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Linezolidrationale1.0.pdf (13 June 2012, date last accessed).
23. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for antiinfective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7.
24. Janmahasatian S, Duffull SB, Ash S et al. Quantification of lean body weight. Clin Pharmacokinet 2005; 44: 1051-65.
25. Morales E, Praga M. The effect of weight loss in obesity and chronic kidney disease. Curr Hypertens Rep 2012; 14: 170-6.
26. Puzniak LA, Paap CM, Durham LK et al. Effect of body weight on the clinical outcomes of treatment of complicated skin and skin structure infections (cSSTI) caused by methicillin-resistant Staphylococcus aureus (MRSA): results from 3 randomized controlled trials of linezolid and vancomycin. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract L1-1749, p. 134. American Society for Microbiology, Washington, DC, USA.
27. Boak LM, Li J, Rayner CR et al. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother 2007; 51: 1287-92.
28. Plock N, Buerger C, Joukhadar C et al. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos 2007; 35: 1816-23.